IPIX (Innovation Pharmaceuticals) Buyback Yield %: 0.00 (As of Jun. 25, 2026)


What is Innovation Pharmaceuticals Buyback Yield %?

Innovation Pharmaceuticals IPIX Buyback Yield % is 0.00 as of Jun. 25, 2026.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Innovation Pharmaceuticals's current buyback yield was 0.00%.

Innovation Pharmaceuticals Buyback Yield % Related Terms

Innovation Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Buyback Yield % Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.04 -4.21 0.00 0.00

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IPIX vs AXIM, RNAZ, APTX: Buyback Yield % Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Buyback Yield % falls into.


Innovation Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Innovation Pharmaceuticals's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 10.36696
=0.00%

Innovation Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 6.220176
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Innovation Pharmaceuticals (IPIX) has a Buyback Yield % of 0.00 as of Jun. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Buyback Yield % too high?
Innovation Pharmaceuticals' current Buyback Yield % is 0.00.
How does Innovation Pharmaceuticals' Buyback Yield % compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Buyback Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Buyback Yield % is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.